Precision Oncology in Solid Cancer
We will discuss agnostic approaches that go beyond national, regional, and organ-specific methods by learning about the current and near future of Precision Oncology using gene panel tests. This symposium is an agonistic session that integrates themes proposed by the JSMO Academic Planning Committee (JSMO-APC)
Current Status and Future Perspectives for Biliary Tract Cancer in Asian Countries
This session will review the epidemiological status of biliary tract cancer in Asia, the current state of treatments, and the prospects for disease management. After the conference, we will prepare a paper on the subject for publication in a scientific journal.
Challenges of Breast Cancer Research Collaboration Across Asia
We will discuss how to organize investigator-led clinical trials in Japan and East/South-East Asia, including epidemiology, clinical practice, and operating system of the clinical trials of each country, and prospects for the future development of novel treatment across Asia.
Facilitation of Asian Collaboration in Cancer Clinical Trials
The formation of a clinical trial network with Asian countries plays an extremely important role in order to increase the presence of Asia as the third pole following the U.S. and Europe, and to increase the role of the Japanese Society of Medical Oncology among academic community in Asia. The Japanese government is reinforcing the Asian Human Well-Being Initiative and AMED has recently launched the Asian Clinical Trials Network Project. In this session, we will invite speakers from Asian countries and discuss the future prospects for the Asian collaboration in clinical trials.
Artificial Intelligence in Oncology and Therapeutics
Impact of COVID-19 on Clinical Practice and Research in Oncology
AI Oncology: Development Status and Perspectives
Liquid Biopsy for Clinical Implementation
CAR-T and New Generation Therapy in Asia-Pacific
The Geriatric Oncology, Past, Present and Future
Future Perspectives of Immunotherapy for mCRC
To discuss the status and prospects for the development of immunotherapy for colorectal cancer.
Current Status and Future Perspectives of Immunotherapy for Advanced Gastric Cancer
To discuss expectations of new strategies to manage gastric cancer from recent data.
Current Status and Future Perspectives of Immunotherapy for Advanced Esophageal Cancer
For several years, there have been no new drugs available for esophageal cancer and no phase III trials have been reported. Recently, the KEYNOTE181 and OPRA phase III trials have reported the superiority of ICI vs chemotherapeutic regimens as second-line therapy and the results of ICI as first-line treatment are also expected to be published later this year. Moreover, approval of nivolumab as second-line therapy based is expected next year based on the results of an expanded clinical trial. Thus, this is the best time to review the status and prospects of immunotherapy for esophageal cancer.
Cutting-edge Perioperative Treatments for Pancreatic Cancer
Peri-operative adjuvant chemotherapy as standard treatment for pancreatic cancer has changed significantly with the introduction of FOLFIRINOX adjuvant therapy (as reported from abroad) and neoadjuvant chemotherapy with gemcitabine and S1 (as reported from Japan). As a result, there are more therapeutic options for patients with unresectable pancreatic cancers and there is much debate on the indication and effectiveness of these treatments. In this session, we will review the current status in Japan and other countries and discuss the future development of treatment strategies.
Systemic Therapy for Advanced Hepatocellular Carcinoma- New Standards and Future Perspectives
Several new drug therapies have become available for patients with hepatocellular carcinoma (HCC). However, several questions remain unanswered. Here, we will discuss issues such as sequential therapy and treatment choice for HCC patients with reduced liver reserve and severe vascular invasion.
Challenges of Combination Immunotherapy for Lung Cancer
Perspectives in Translational Biomarker Research for Immune Checkpoint Inhibitors
Future Prospects of Molecular Targeted Therapy for Lung Cancer Patients with Driver Mutation
Cutting Edge AML Treatments
Gene-panel tests have evolved considerably in hamatologic malignacies as well as in solid cancers. Although no new drug had been available for AML for a long period, FLT3 inhibitors were approved recently. Also, additional approval for a Bcl-2 inhibitor is expected in the near future. In addition, transplantation strategies have been improved significantly, leading to better outcomes. In this symposium, we will focus on the development of gene panel testing for AML in Japan and the latest treatments.
Antibody Drug Conjugates for Hematologic Malignancies
Upon binding to the target antigens expressed on tumor cells, antibody-drug conjugates (ADCs) are incorporated into the cells along with the conjugated cytotoxic drug, thereby showing high cytotoxic effects. In this symposium, the latest developments of novel ADCs for the treatment of AML, MM, DLBCL and T-cell lymphoma will be reported.
MRD-guided Therapies for Hematologic Malignancies
Minimum residual disease (MRD) is a potent surrogate marker to predict recurrence and prognosis. In hematopoietic malignancies, MRD is measured at clitical time points during the treatment to make informed decisions on subsequent treatments. In this symposium, we will discuss MRD-based treatment strategies in FLT3-ITD mutation-positive AML, ALL, malignant lymphoma, and MM.
Development and Future Perspectives of Immune Checkpoint Inhibitors for Breast Cancer
In breast cancer, atezolizumab was approved for the treatment of triple-negative advanced recurrent breast cancer following the results of the IMpassion130 trial. This will be the starting point for the expansion of indications to other subtypes, preoperative and postoperative treatments. In addition, more effective use of immune checkpoint inhibitors in breast cancer with “cold” tumors and biomarker studies are needed. On the other hand, management of immune checkpoint inhibitors is necessary to ensure their effective and safe use. In this session, we will comprehensively discuss and deepen our understanding of the nascent field of breast cancer immunotherapy.
De-escalating and Escalating Treatment for Breast Cancer
Advances in surgery, drugs, and radiation therapy have led to significant improvements in prognosis in breast cancer, but the negative aspects of escalating therapy, such as adverse events, poor quality of life, and increased costs, have become critical issues. In this session, we discuss the evidence, development status, and future needs of de-escalation therapy, taking into account the individual risks of each patient.
Back to the Future; Re-Learning the Biology of Breast Cancer
Tamoxifen, the most classic of molecular targeting drugs, was approved for breast cancer before its mechanism of action against its target, the estrogen receptor, was understood. At present, several molecularly targeted therapies are available. On its core is a fundamental understanding of the biology of breast cancer proliferation and progression. In this session we take another look back at the biology of classical hormone receptors, PARPs, cyclins, and delve into new targets.
PARP Inhibitor, Anti-angiogenesis, or Both? -Best Combination for Ovarian Cancer-
Immune Checkpoint Blockade for Gynecological Malignancy
A New Era of Genitourinary Cancer Precision Medicine
Precision medicine will be introduced into urological cancer by 2021 with high probability. In particular, PARP inhibitors for prostate cancer and EGFR inhibitors for urothelial cancer are attracting attention as promising treatment options based on companion diagnoses.
By participating this program, participants will be able to gain the latest knowledge about precision medicine of urological cancers and learn how to use them appropriately in clinical practice.
Identifying and Managing AEs in IO-TKI Combination
In December 2019, combination therapy of ICI and TKI was added to the treatment of kidney cancer. While synergistic anti-tumor effects of drugs with different mechanisms of action are expected, adverse event management becomes more complicated and difficult, therefore, collaboration between different professions is essential for the treatment. In this session, particitants will learn the roles of physicians, nurses, and pharmacists, and acquire practical know-how through case discussions.
New Perspectives on the Treatment of Head and Neck Cancer
Immune checkpoint inhibitors have become the standard of care as primary treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma. New prospects for future treatment of head and neck cancers are being explored in 1) combination with immune checkpoint inhibitors, 2) combination with radiotherapy for locally advanced cancers, and 3) establishment of new biomarkers.
New Perspectives on the Treatment of Thyroid Cancer
Thyroid cancer is a carcinoma with actionable genetic abnormalities, as a result, development of molecular targeting drugs has been very active. In this session, we will provide the latest information regarding the status of approved drugs and the latest therapeutic developments for each tissue type.
Immunotherapy and Targeted Therapy for Rare Cancers
Immunotherapies with immune checkpoint inhibitors have been shown to be effective in many types of cancers but have not been established in rare cancers such as sarcoma, partly because of the difficulty of conducting clinical trials. In this symposium, the therapeutic efficacy of immune checkpoint inhibitors and T-cell therapy in sarcoma as a whole and special subtypes and future strategies for the clinical development of immunotherapy in rare cancers will be discussed.
Advances in Molecular Therapeutics: Potential Targets and Novel Strategies
KRAS-mutated tumors, which have been described as undruggable, have received renewed interest with the development of G12C inhibitors. This session delves on the status of therapeutic development for KRAS mutation-positive tumors, including G12C inhibitors. We will also discuss therapeutic development for KRAS mutation-positive tumors, an important subset of non-small cell lung cancer, including drug development for EGFR exon 20 insertion mutations, therapeutic strategies for osimertinib resistance, and the potential for IO combination therapy.
Immunooncology: the Role of the Tumor Microenvironment
Immunotherapy for malignant tumors is taking a center stage. This session will examine the role of the tumor microenvironment and explores its associations with host microbiomes, metabolism, and responses to immunotherapy and other treatments strategies. We also explore how the tumor microenvironment can be reprogrammed to enhance the therapeutic efficacy of anticancer therapy and examine clinical applications.
Targeting the Tumor Microenvironment and Microbiome in the New Era of Cancer Immunotherapy
This session will cover an introductory overview and the latest findings on development strategies for new cancer immunotherapies following immune checkpoint inhibitors, including a focus on new approaches to microbiome-mediated immune modification and modulation of the tumor microenvironment (TME) by expert overseas researchers, followed by summary and problem-solving by discussants, to provide participants with a shared understanding of the barriers and issues related to next-generation cancer immunotherapy.
Tumor Agnostic Drug Development and Approval
- A New Phase for Oncology Precision Medicine –
Even after the tumor agnostic approval of pembrolizumab for advanced solid tumors with high microsatellite instability (MSI-High) and enutrectinib for advanced or recurrent NTRK fusion-positive solid tumors, there are still many unresolved problems for Tissue Agnostic Drug Development/Approval. In this session, we will focus on the current status and challenges of tumor agnostic clinical trials through discussion together with medical oncologists from academia, pharmaceutical companies, statisticians and both the FDA and PMDA regulatory agencies who are working at the forefront of Tissue Agnostic Oncology Drug Development in Japan and the United States.
Adjuvant Clinical Trials in the Precision Medicine Era
It is highly expected that liquid biopsy will be widely available soon in general clinical practice, and accumulating data have been published in many cancer types with regard to the role of liquid biopsy for predicting recurrence after curative surgery. In this symposium, we will understand the history and current status of "tissue biopsy" gene tests for predicting tumor recurrence at first, and then review current available evidence for "liquid biopsy" tests. Further, we will discuss the optimal design and analysis of clinical trials for developing personalized treatment with liquid biopsies. These discussion will help to understand the future development of liquid biopsy.
Health Economic Evaluation in Oncology
While new cancer treatments become available in clinical practice, more concerns on the cost of the drugs are growing. Accordingly, the role of health technology assessment (HTA) such as cost-effectiveness assessment based on the results of clinical trials has been now widely recognized. However, Sustaining the HTA system will be difficult unless it has value for four stakeholders; "patients," "medical practitioners," "financiers (country)", and "pharmaceutical companies". In this symposium, we will discuss the future of Japanese HTA in oncology with each of these stakeholders.
Influence of Recent Regulatory Changes on Clinical Trials
The ICH-GCP is currently undergoing a major renovation with the modernization of the ICH-E8 guideline (general guidelines for clinical trials) and the revision of ICH-E6(R3). The scope of the GCP renovation includes not only clinical trials for pharmaceutical approval but also post-marketing trials and clinical trials referring to Real World Data. Also the enforcement of the Clinical Trials Act and the new ethical guidelines will give substantial influences on academic clinical trials. In this session, we will share the latest information on the changes of clinical trial regulations and discuss the role of investigator-initiated clinical trials.
Implementation Strategies of Cancer Survivorship Care